Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Real World Observational Study On The Use Of Akynzeo® (Netupitant/Palonosetron) For The Prevention Of Nausea and Vomiting in Oncology Patients Receiving Highly Emetogenic Chemotherapy (HEC) Over Multiple Cycles.

NCT03649230 is registered in ClinicalTrials.gov with Purdue Pharma, Canada as lead sponsor.

NCT NCT03649230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03649230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Real World Observational Study On The Use Of Akynzeo® (Netupitant/Palonosetron) For The Prevention Of Nausea and Vomiting in Oncology Patients Receiving Highly Emetogenic Chemotherapy (HEC) Over Multiple Cycles.
Lead sponsor
Purdue Pharma, Canada
Phase
Observational
Overall status
Completed
Start date
October 3, 2018
Completion date
January 30, 2020
Enrollment
207 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced nausea and vomiting